Novartis announces FDA approval of MET inhibitor Tabrecta (capmatinib)for metastatic non-small cell lung cancer with METex14
11 Maggio 2020
Novartis has announced that the US Food and Drug Administration (FDA) approved Tabrecta (capmatinib), an oral MET inhibitor for adult patients with metastatic non-small cell lung
